Alexandre Harari

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


135 publications

En préparation
 
CytoBatchNorm: an R package with graphical interface for batch effects correction of cytometry data
Granjeaud Samuel, Abdellaoui Naoill, Chrétien Anne-Sophie, Woitrain Eloise, Pineau Laurent, Ninni Sandro, Harari Alexandre, Arnaud Marion, Montaigne David, Staels Bart et al..
[DOI][serval:BIB_BCBDB7DD5F2B]
In press
 
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy.
Huber F., Arnaud M., Stevenson B.J., Michaux J., Benedetti F., Thevenet J., Bobisse S., Chiffelle J., Gehert T., Müller M. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_14DC47CDBB48]
 
Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Pétremand R., Chiffelle J., Bobisse S., Perez MAS, Schmidt J., Arnaud M., Barras D., Lozano-Rabella M., Genolet R., Sauvage C. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_88A45E78E09C]
 
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Pétremand R., Chiffelle J., Bobisse S., Perez MAS, Schmidt J., Arnaud M., Barras D., Lozano-Rabella M., Genolet R., Sauvage C. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AF334A302D27]
2024
 
Predicting Antigen-Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist.
Perez MAS, Chiffelle J., Bobisse S., Mayol-Rullan F., Bugnon M., Bragina M.E., Arnaud M., Sauvage C., Barras D., Laniti D.D. et al., 2024/10. Advanced science, 11 (40) pp. e2405949. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0C9B82A244FB]
 
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.
Chiffelle J., Barras D., Pétremand R., Orcurto A., Bobisse S., Arnaud M., Auger A., Rodrigo B.N., Ghisoni E., Sauvage C. et al., 2024/09/10. Immunity, 57 (10) pp. 2466-2482. Peer-reviewed.
[DOI][Pmid][serval:BIB_3BC38E07E916]
Personalized cancer T-cell therapy takes the stage, mirroring vaccine success.
Chiffelle J., Harari A., 2024/08/05. The Journal of experimental medicine, 221 (8). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CEA5DB463B31]
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Morotti M., Grimm A.J., Hope H.C., Arnaud M., Desbuisson M., Rayroux N., Barras D., Masid M., Murgues B., Chap B.S. et al., 2024/05. Nature, 629 (8011) pp. 426-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5FCB44D6E4AA]
Deep learning predictions of TCR-epitope interactions reveal epitope-specific chains in dual alpha T cells.
Croce G., Bobisse S., Moreno D.L., Schmidt J., Guillame P., Harari A., Gfeller D., 2024/04/13. Nature communications, 15 (1) p. 3211. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5F1F27C4B8D4]
2023
Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
Müller M., Huber F., Arnaud M., Kraemer A.I., Altimiras E.R., Michaux J., Taillandier-Coindard M., Chiffelle J., Murgues B., Gehret T. et al., 2023/11/14. Immunity, 56 (11) pp. 2650-2663.e6. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_809F4EAB21AB]
Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics.
Romanens L., Chaskar P., Marcone R., Ryser S., Tille J.C., Genolet R., Heimgartner-Hu K., Heimgartner K., Moore J.S., Liaudet N. et al., 2023/11/01. International journal of cancer, 153 (9) pp. 1568-1578. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA0A2EA97728]
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
 
Deep learning predictions of TCR-epitope interactions reveal epitope-specific chains in dual alpha T cells
Giancarlo Croce, Sara Bobisse, Dana Léa Moreno, Julien Schmidt, Philippe Guillame, Alexandre Harari, David Gfeller, 2023/09/16..
[DOI][serval:BIB_0A68625521D8]
HIV specific Th1 responses are altered in Ugandans with HIV and Schistosoma mansoni coinfection.
Obuku A.E., Lugemwa J.K., Abaasa A., Joloba M., Ding S., Pollara J., Ferrari G., Harari A., Pantaleo G., Kaleebu P., 2023/08/29. BMC immunology, 24 (1) p. 25. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_62C12F4E0858]
Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
Fallet B., Foglierini M., Porret R., Alcaraz-Serna A., Sauvage C., Jenelten R., Caplanusi T., Gilliet M., Perez L., Fenwick C. et al., 2023/08. The Journal of infection, 87 (2) pp. 111-119. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9DA429039D3E]
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.
Racle J., Guillaume P., Schmidt J., Michaux J., Larabi A., Lau K., Perez MAS, Croce G., Genolet R., Coukos G. et al., 2023/06/13. Immunity, 56 (6) pp. 1359-1375.e13. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9BA5A00EAA19]
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.
Ahmed R., Lozano L.E., Anastasio A., Lofek S., Mastelic-Gavillet B., Navarro Rodrigo B., Nguyen S., Dartiguenave F., Rodrigues-Dias S.C., Cesson V. et al., 2023/06/08. Cancers, 15 (12) p. 3114. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4F3B91EA43E2]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R., Bobisse S., Chiffelle J., Arnaud M., Petremand R., Queiroz L., Michel A., Reichenbach P., Cesbron J., Auger A. et al., 2023/04/24. Cell reports methods, 3 (4) p. 100459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC23FF064822]
Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.
Fritah H., Graciotti M., Lai-Lai Chiang C., Huguenin-Bergenat A.L., Petremand R., Ahmed R., Guillaume P., Schmidt J., Stevenson B.J., Gfeller D. et al., 2023/04/21. iScience, 26 (4) p. 106288. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5198D931AE8]
Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8(+ )T-cell epitopes.
Gfeller D., Schmidt J., Croce G., Guillaume P., Bobisse S., Genolet R., Queiroz L., Cesbron J., Racle J., Harari A., 2023/01/18. Cell systems, 14 (1) pp. 72-83.e5. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_53359DC7F7C1]
Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Lofek S., Wyss T., Melero I., de Vries IJM, Harari A., Romero P., Kandalaft L.E. et al., 2023. Frontiers in immunology, 14 p. 1119371. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_93460C0AF320]
Towards next-generation TIL therapy: TILs enriched in neoepitope-specific T cells.
Arnaud M., Coukos G., Harari A., 2023/01. Clinical and translational medicine, 13 (1) pp. e1174. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_803001E6E3E3]
2022
Microfluidic T Cell Selection by Cellular Avidity.
Ashby J.F., Schmidt J., Kc N., Kurum A., Koch C., Harari A., Tang L., Au S.H., 2022/08. Advanced healthcare materials, 11 (16) pp. e2200169. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9101DBCC66E2]
 
Immune pressure sculps tumor cells and trims high-quality mutations.
Bassani-Sternberg M., Harari A., 2022/07/11. Cancer cell, 40 (7) pp. 717-719. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4774C8AD358C]
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
Arnaud M., Chiffelle J., Genolet R., Navarro Rodrigo B., Perez MAS, Huber F., Magnin M., Nguyen-Ngoc T., Guillaume P., Baumgaertner P. et al., 2022/05. Nature biotechnology, 40 (5) pp. 656-660. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_18BFBDDF727B]
A new workflow combining magnetic cell separation and impedance-based cell dispensing for gentle, simple and reliable cloning of specific CD8+ T cells.
Ben Khelil M., Aeberli L., Perchaud M., Genolet R., Abdeljaoued S., Borg C., Binda D., Harari A., Jandus C., Muller G. et al., 2022/04. SLAS technology, 27 (2) pp. 130-134. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_97892CDB341E]
High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure.
Schrijver I.T., Karakike E., Théroude C., Baumgartner P., Harari A., Giamarellos-Bourboulis E.J., Calandra T., Roger T., 2022/02/11. Intensive care medicine experimental, 10 (1) p. 5. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_79AC142AD176]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
 
Predictions of immunogenicity reveal potent SARS-CoV-2 CD8+ T-cell epitopes
Gfeller David, Schmidt Julien, Croce Giancarlo, Guillaume Philippe, Bobisse Sara, Genolet Raphael, Queiroz Lise, Cesbron Julien, Racle Julien, Harari Alexandre, 2022..
[DOI][serval:BIB_97E1B8EF6136]
2021
Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers.
Kandalaft L.E., Harari A., 2021/11/19. Cancers, 13 (22) p. 5819. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6B925EAAEE85]
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Harari A., Sarivalasis A., de Jonge K., Thierry A.C., Huber F., Boudousquie C., Rossier L., Orcurto A., Imbimbo M., Baumgaertner P. et al., 2021/11/18. Cancers, 13 (22) p. 5801. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A292F2251A7]
Microfluidic Device for Droplet Pairing by Combining Droplet Railing and Floating Trap Arrays.
Duchamp M., Arnaud M., Bobisse S., Coukos G., Harari A., Renaud P., 2021/09/06. Micromachines, 12 (9) p. 1076. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_550F1A17928D]
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H. et al., 2021/07/20. Cell reports, 36 (3) p. 109412. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_745449157CA6]
Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Tanyi J.L., Chiang C.L., Chiffelle J., Thierry A.C., Baumgartener P., Huber F., Goepfert C., Tarussio D., Tissot S., Torigian D.A. et al., 2021/05/04. NPJ vaccines, 6 (1) p. 68. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2126872FC2DC]
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Tanyi J.L., Chiang C.L., Chiffelle J., Thierry A.C., Baumgartener P., Huber F., Goepfert C., Tarussio D., Tissot S., Torigian D.A. et al., 2021/03/15. NPJ vaccines, 6 (1) p. 36. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8E270F9DEDE8]
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting.
Schmidt J., Smith A.R., Magnin M., Racle J., Devlin J.R., Bobisse S., Cesbron J., Bonnet V., Carmona S.J., Huber F. et al., 2021/02/16. Cell reports. Medicine, 2 (2) p. 100194. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9AA90BD897A9]
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.
Cachot A., Bilous M., Liu Y.C., Li X., Saillard M., Cenerenti M., Rockinger G.A., Wyss T., Guillaume P., Schmidt J. et al., 2021/02. Science advances, 7 (9) pp. eabe3348. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7FDE10B2A046]
The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
Arnaud M., Bobisse S., Chiffelle J., Harari A., 2021. Frontiers in immunology, 12 p. 701636. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_132C3057D946]
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.
Baumgaertner P., Sankar M., Herrera F.G, Benedetti F., Barras D., Thierry A.C., Dangaj D., Kandalaft L.E., Coukos G., Xenarios I. et al., 2021. Frontiers in immunology, 12 p. 633910. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E707FFE34C52]
2020
 
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon P.O., Harari A., Auger A., Murgues C., Zangiacomi V., Rubin O., Ellefsen Lavoie K., Guillemot L., Navarro Rodrigo B., Nguyen-Ngoc T. et al., 2020/12. Cytotherapy, 22 (12) pp. 780-791. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30851676B0A7]
Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes
Chong Chloe, Müller Markus, Pak HuiSong, Harnett Dermot, Huber Florian, Grun Delphine, Leleu Marion, Auger Aymeric, Arnaud Marion, Stevenson Brian J. et al., 2020/12. Nature Communications, 11 (1). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_03EA897A1141]
 
Structural dissimilarity from self drives neoepitope escape from immune tolerance.
Devlin J.R., Alonso J.A., Ayres C.M., Keller GLJ, Bobisse S., Vander Kooi C.W., Coukos G., Gfeller D., Harari A., Baker B.M., 2020/11. Nature chemical biology, 16 (11) pp. 1269-1276. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_186F0AD1C570]
 
Biotechnologies to tackle the challenge of neoantigen identification.
Arnaud M., Duchamp M., Bobisse S., Renaud P., Coukos G., Harari A., 2020/10. Current opinion in biotechnology, 65 pp. 52-59. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_78FA51F85D77]
T-cell repertoire analysis and metrics of diversity and clonality.
Chiffelle J., Genolet R., Perez M.A., Coukos G., Zoete V., Harari A., 2020/10. Current opinion in biotechnology, 65 pp. 284-295. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_598F3EDCA20B]
 
Antitumour dendritic cell vaccination in a priming and boosting approach.
Harari A., Graciotti M., Bassani-Sternberg M., Kandalaft L.E., 2020/09. Nature reviews. Drug discovery, 19 (9) pp. 635-652. Peer-reviewed.
[DOI][Pmid][serval:BIB_14F09B31BAF0]
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A., Hottinger A., Wolf B., Navarro Rodrigo B., Ochoa de Olza M., Auger A., Kuntzer T., Comte D., Zimmer V., Gannon P. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e001155. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C930B13A53AD]
 
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Wyss T., Inoges S., de Vries IJM, Dartiguenave F., Jichlinski P., Derrè L., Coukos G. et al., 2020/06/23. European journal of cancer, 135 pp. 173-182. Peer-reviewed.
[DOI][Pmid][serval:BIB_2DED61B64BB4]
Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines.
Graciotti M., Marino F., Pak H., Baumgaertner P., Thierry A.C., Chiffelle J., Perez MAS, Zoete V., Harari A., Bassani-Sternberg M. et al., 2020/06/02. Vaccines, 8 (2). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0A84027C58CB]
 
Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients.
Rockinger G.A., Guillaume P., Cachot A., Saillard M., Speiser D.E., Coukos G., Harari A., Romero P.J., Schmidt J., Jandus C., 2020/05. Journal for immunotherapy of cancer, 8 (1) pp. e000435. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EBA81BA22D33]
Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine.
Boudousquié C., Boand V., Lingre E., Dutoit L., Balint K., Danilo M., Harari A., Gannon P.O., Kandalaft L.E., 2020/01/14. Vaccines, 8 (1). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8FCD2C6F2CCA]
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure.
Vigano S., Bobisse S., Coukos G., Perreau M., Harari A., 2020. Frontiers in immunology, 11 p. 1350. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_19C82F6CB34E]
 
High-throughput identification of human antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells using soluble pMHC multimers.
Magnin M., Guillaume P., Coukos G., Harari A., Schmidt J., 2020. Methods in enzymology, 631 pp. 21-42. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FD66E29F7790]
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.
Bianchi V., Harari A., Coukos G., 2020. Frontiers in immunology, 11 p. 1215. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B0551F2A3933]
2019
 
Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry.
Girotra M., Thierry A.C., Harari A., Coukos G., Naveiras O., Vannini N., 2019/12/26. Journal of visualized experiments 154. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DE9A27B5B4E4]
Microfluidic device performing on flow study of serial cell-cell interactions of two cell populations.
Duchamp M., Dahoun T., Vaillier C., Arnaud M., Bobisse S., Coukos G., Harari A., Renaud P., 2019/12/09. RSC advances, 9 (70) pp. 41066-41073. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E280C4A083E]
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A., Boudousquié C., Balint K., Stevenson B.J., Gannon P.O., Iancu E.M., Rossier L., Martin Lluesma S., Mathevet P., Sempoux C. et al., 2019/11/26. Journal of translational medicine, 17 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_313F7CD9FDBC]
 
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.
Racle J., Michaux J., Rockinger G.A., Arnaud M., Bobisse S., Chong C., Guillaume P., Coukos G., Harari A., Jandus C. et al., 2019/11. Nature biotechnology, 37 (11) pp. 1283-1286. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9A8D08A5BC6]
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8<sup>+</sup> T cells.
Mastelic-Gavillet B., Navarro Rodrigo B., Décombaz L., Wang H., Ercolano G., Ahmed R., Lozano L.E., Ianaro A., Derré L., Valerio M. et al., 2019/10/10. Journal for immunotherapy of cancer, 7 (1) p. 257. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC3C085DEA43]
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
Bassani-Sternberg Michal, Digklia Antonia, Huber Florian, Wagner Dorothea, Sempoux Christine, Stevenson Brian J., Thierry Anne-Christine, Michaux Justine, Pak HuiSong, Racle Julien et al., 2019/08/08. Frontiers in Immunology, 10 p. 1832. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0144F5D289B5]
 
High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.
Costa-Nunes C., Cachot A., Bobisse S., Arnaud M., Genolet R., Baumgaertner P., Speiser D.E., Sousa Alves P.M., Sandoval F., Adotévi O. et al., 2019/07/15. Clinical cancer research, 25 (14) pp. 4320-4331. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_99ED3D648751]
Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.
Broggi MAS, Maillat L., Clement C.C., Bordry N., Corthésy P., Auger A., Matter M., Hamelin R., Potin L., Demurtas D. et al., 2019/05/06. The Journal of experimental medicine, 216 (5) pp. 1091-1107. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_83C31BFEAA5C]
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera F.G., Valerio M., Berthold D., Tawadros T., Meuwly J.Y., Vallet V., Baumgartner P., Thierry A.C., De Bari B., Jichlinski P. et al., 2019/02/01. International journal of radiation oncology, biology, physics, 103 (2) pp. 320-334. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8A5A6B3310C5]
2018
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
[DOI][WoS][Pmid][serval:BIB_641968BB356B]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi J.L., Bobisse S., Ophir E., Tuyaerts S., Roberti A., Genolet R., Baumgartner P., Stevenson B.J., Iseli C., Dangaj D. et al., 2018/04/11. Science translational medicine, 10 (436) pp. NA. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBC10D090AEF]
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_10AE95ADCEE8]
2017
 
Dysregulated Innate Lymphocytes in Patients With Primary Antibody Deficiency Treated With Intravenous Immunoglobulin.
Vigano S., Trabanelli S., Indulsi F., Salomé B., Harari A., Romero P., Helbling A., Jandus C., Jandus P., 2017. Journal of investigational allergology & clinical immunology, 27 (6) pp. 394-396. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AFE710182D6B]
2016
Effect of Schistosoma mansoni Infection on Innate and HIV-1-Specific T-Cell Immune Responses in HIV-1-Infected Ugandan Fisher Folk.
Obuku A.E., Asiki G., Abaasa A., Ssonko I., Harari A., van Dam G.J., Corstjens P.L., Joloba M., Ding S., Mpendo J. et al., 2016/07. AIDS research and human retroviruses, 32 (7) pp. 668-675. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FB39146F35F0]
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Martin Lluesma S., Wolfer A., Harari A., Kandalaft L.E., 2016/05/03. Biomedicines, 4 (2) pp. NA. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3E1510893037]
 
Neoantigen-based cancer immunotherapy.
Bobisse S., Foukas P.G., Coukos G., Harari A., 2016. Annals of Translational Medicine, 4 (14) p. 262. Peer-reviewed.
[DOI][Pmid][serval:BIB_F74C06B31066]
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Yuan J., Hegde P.S., Clynes R., Foukas P.G., Harari A., Kleen T.O., Kvistborg P., Maccalli C., Maecker H.T., Page D.B. et al., 2016. Journal For Immunotherapy of Cancer, 4 p. 3. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EB4FE1C2D1D7]
 
Personalized approaches to active immunotherapy in cancer
Ophir Eran, Bobisse Sara, Coukos George, Harari Alexandre, Kandalaft Lana E., 2016/01. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1865 (1) pp. 72-82. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_01C8158A4FDC]
2015
Combined Use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis.
Rozot V., Patrizia A., Vigano S., Mazza-Stalder J., Idrizi E., Day C.L., Perreau M., Lazor-Blanchet C., Ohmiti K., Goletti D. et al., 2015. Clinical Infectious Diseases, 60 (3) pp. 432-437. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_35203E0F848B]
 
High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.
Chevalier M.F., Bobisse S., Costa-Nunes C., Cesson V., Jichlinski P., Speiser D.E., Harari A., Coukos G., Romero P., Nardelli-Haefliger D. et al., 2015. Oncoimmunology, 4 (10) pp. e1029702. Peer-reviewed.
[DOI][Pmid][serval:BIB_FC441F50334F]
Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.
Delaloye J., Filali-Mouhim A., Cameron M.J., Haddad E.K., Harari A., Goulet J.P., Gomez C.E., Perdiguero B., Esteban M., Pantaleo G. et al., 2015. Journal of Virology, 89 (7) pp. 3819-3832. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3F54B19290C2]
2014
CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression.
Viganò S., Banga R., Bellanger F., Pellaton C., Farina A., Comte D., Harari A., Perreau M., 2014. Plos Pathogens, 10 (9) pp. e1004380. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C7F89A3A803E]
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
Romano E., Michielin O., Voelter V., Laurent J., Bichat H., Stravodimou A., Romero P., Speiser D.E., Triebel F., Leyvraz S. et al., 2014. Journal of Translational Medicine, 12 p. 97.
[URN][DOI][WoS][Pmid][serval:BIB_09C5EADDDF4D]
2013
 
Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4(+) T cells in active disease.
Perreau M., Rozot V., Welles H.C., Belluti-Enders F., Vigano S., Maillard M., Dorta G., Mazza-Stalder Jesica, Bart P.A., Roger T. et al., 2013. European Journal of Immunology, 43 (4) pp. 939-948.
[DOI][WoS][Pmid][serval:BIB_E956D462F256]
 
Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease.
Rozot V., Vigano S., Mazza-Stalder J., Idrizi E., Day C.L., Perreau M., Lazor-Blanchet C., Petruccioli E., Hanekom W., Goletti D. et al., 2013. European Journal of Immunology, 43 (6) pp. 1568-1577.
[DOI][WoS][Pmid][serval:BIB_7269592AD615]
Rapid Perturbation in Viremia Levels Drives Increases in Functional Avidity of HIV-specific CD8 T Cells.
Viganò S., Bellutti Enders F., Miconnet I., Cellerai C., Savoye A.L., Rozot V., Perreau M., Faouzi M., Ohmiti K., Cavassini M. et al., 2013. Plos Pathogens, 9 (7) pp. e1003423.
[URN][DOI][WoS][Pmid][serval:BIB_D20B27FA77D4]
2012
Functional avidity: a measure to predict the efficacy of effector T cells?
Viganò S., Utzschneider D.T., Perreau M., Pantaleo G., Zehn D., Harari A., 2012. Clinical and Developmental Immunology, 2012 p. 153863. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B0CB84A1CD5B]
 
HLA-B7-Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis.
Jilek S., Schluep M., Harari A., Canales M., Lysandropoulos A., Zekeridou A., Pantaleo G., Du Pasquier R.A., 2012. Journal of Immunology, 188 (9) pp. 4671-4680. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A0D2159CC0F6]
 
Modulation of human memory T-cell function by different antigen-presenting cells.
Perreau M., Welles H.C., Harari A., Calandra T., Roger T., Pantaleo G., 2012. European Journal of Immunology, 42 (3) pp. 799-802.
[DOI][WoS][Pmid][serval:BIB_426696050FC2]
 
Mycobacterium tuberculosis-specific CD8 T cells are functionally and phenotypically different between latent infection and active disease
Rozot V., Vigano S., Mazza-Stalder J., Perreau M., Goletti D., Bart P. A., Nicod L., Pantaleo G., Harari A., 2012. p. 598 dans European Congress of Immunology, Immunology.
[WoS][serval:BIB_D7303CF13CEC]
 
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.
Harari A., Rozot V., Cavassini M., Enders F.B., Vigano S., Tapia G., Castro E., Burnet S., Lange J., Moog C. et al., 2012. European Journal of Immunology, 42 (11) pp. 3038-3048.
[DOI][WoS][Pmid][serval:BIB_0D93650C7F77]
Positive and negative regulation of cellular immune responses in physiologic conditions and diseases.
Viganò S., Perreau M., Pantaleo G., Harari A., 2012. Clinical and Developmental Immunology, 2012 p. 485781.
[URN][DOI][WoS][Pmid][serval:BIB_4F81E9CDB066]
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
Gómez C.E., Perdiguero B., Jiménez V., Filali-Mouhim A., Ghneim K., Haddad E.K., Quakkelaar E.D., Quakkerlaar E.D., Delaloye J., Harari A. et al., 2012. Plos One, 7 (4) pp. e35485.
[URN][DOI][WoS][Pmid][serval:BIB_C791C445724A]
 
The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.
Perreau M., Welles H.C., Pellaton C., Gjoksi B., Potin L., Martin R., Harari A., Bett A., Casimiro D., Gall J. et al., 2012. Journal of Virology, 86 (11) pp. 6279-6285.
[DOI][WoS][Pmid][serval:BIB_B4299141A4E6]
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.
McNerney R., Maeurer M., Abubakar I., Marais B., McHugh T.D., Ford N., Weyer K., Lawn S., Grobusch M.P., Memish Z. et al., 2012. Journal of Infectious Diseases, 205 (Suppl. 2) pp. S147-S158.
[URN][DOI][WoS][Pmid][serval:BIB_F65424B09DBF]
2011
 
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.
Harari A., Rozot V., Bellutti Enders F., Perreau M., Mazza-Stalder J.M., Nicod L.P., Cavassini M., Calandra T., Blanchet C.L., Jaton K. et al., 2011/03. Nature medicine, 17 (3) pp. 372-376. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C47C605FFBCF]
 
DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa
Perreau M., Welles H.C., Harari A., Hall O., Martin R., Maillard M., Dorta G., Bart P., Kremer E.J., Tartaglia J. et al., 2011. pp. A3 dans AIDS Vaccine 2011 Conference, Aids Research and Human Retroviruses. Peer-reviewed.
[WoS][serval:BIB_5A1662127306]
 
DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.
Perreau M., Welles H.C., Harari A., Hall O., Martin R., Maillard M., Dorta G., Bart P.A., Kremer E.J., Tartaglia J. et al., 2011. Journal of Virology, 85 (19) pp. 9854-9862.
[DOI][WoS][Pmid][serval:BIB_B8BC78EDCB21]
Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors.
Cellerai C., Harari A., Stauss H., Yerly S., Geretti A.M., Carroll A., Yee T., Ainsworth J., Williams I., Sweeney J. et al., 2011. Plos One, 6 (4) pp. e18164.
[URN][DOI][WoS][Pmid][serval:BIB_44B55F68B8CD]
 
Impact of Pre-Existing Immunity on the Selection of Rare Adenovirus Vector Candidates: Implications for HIV Vaccine Development
Perreau M., Welles H.C., Harari A., Potin L., Martin R., Bibert S., Roger T., Calandra T., Bett A., Gall J. et al., 2011. pp. A109 dans AIDS Vaccine 2011 Conference, Aids Research and Human Retroviruses. Peer-reviewed.
[WoS][serval:BIB_52448710FD7A]
Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors.
Quakkelaar E.D., Redeker A., Haddad E.K., Harari A., McCaughey S.M., Duhen T., Filali-Mouhim A., Goulet J.P., Loof N.M., Ossendorp F. et al., 2011. Plos One, 6 (2) pp. e16819.
[URN][DOI][WoS][Pmid][serval:BIB_38370DD8AB46]
 
La signature immunologique - Nouvel outil diagnostique de la tuberculose active  [Immunological signatures: a new tool to diagnose active tuberculosis disease?].
Rozot V., Perreau M., Harari A., Pantaleo G., 2011. Médecine Sciences, 27 (10) pp. 808-811.
[DOI][WoS][Pmid][serval:BIB_3622C4E9C156]
 
Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure.
Miconnet Isabelle, Marrau Angélique, Farina Alex, Taffé Patrick, Vigano Selena, Harari Alexandre, Pantaleo Giuseppe, 2011. Journal of Immunology, 186 (12) pp. 7039-7049. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_89DABB9357FA]
 
Prolonged antiretroviral therapy initiated at seroconversion is associated with a polyfunctional HIV-1-specific T-cell profile comparable to that of long-term non-progressors (LTNPs)
Cellerai C., Harari A., Stauss H., Yerly S., Geretti A. M., Carroll A., Yee T., Ainsworth J., Williams I., Sweeney J. et al., 2011. p. 11 dans 17th Annual Conference of the British HIV Association (BHIVA), HIV Medicine. Peer-reviewed.
[WoS][serval:BIB_1E9A9E9CC7F1]
2010
 
Improvement of the HIV/AIDS vaccine candidate NYVAC-C by deletion of the viral type I IFN inhibitor and/or acquisition of replication competence
Kibler K.V., Perdiguera B., Gomez C.E., Najera J.L., Gonzalez-Sanz R., Jimenez V., Quakkelaar E.D., Melief C.J., Haddad E., Sekaly R. et al., 2010. pp. A137 dans AIDS Vaccine 2010, Aids Research And Human Retroviruses. Peer-reviewed.
[WoS][serval:BIB_2EA9BB35EA17]
 
Modulation of TCR avidity of primary HIV-1-specific CD8 T-cell responses by early and potent antiviral therapy responses
Harari A., Vlgano S., Bellutti Enders F., Cellerai C., Castro E., Cavassini M., Bart P., Pantaleo G., 2010. pp. A7-A8 dans AIDS Vaccine 2010, Aids Research And Human Retroviruses. Peer-reviewed.
[WoS][serval:BIB_4ED69DA1DA17]
 
Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression.
Cellerai C., Perreau M., Rozot V., Enders F.B., Pantaleo G., Harari A., 2010. Journal of Virology, 84 (8) pp. 3868-3878.
[DOI][WoS][Pmid][serval:BIB_241EC3C720DF]
2009
 
Antigen exposure regulates the balance between proliferating and cytotoxic subsets of virus-specific CD8 T-cells : P16-32
Cellerai C., Perreau M., Rozot V., Enders F. Bellutti , Bart P., Pantaleo G., Harari A., 2009. p. 261 dans AIDS Vaccine 2009, Retrovirology. Peer-reviewed.
[DOI][WoS][serval:BIB_6703D99F50F4]
 
Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.
Mooij P., Balla-Jhagjhoorsingh S.S., Beenhakker N., van Haaften P., Baak I., Nieuwenhuis I.G., Heidari S., Wolf H., Frachette M.J., Bieler K. et al., 2009. Journal of Virology, 83 (11) pp. 5881-5889.
[DOI][WoS][Pmid][serval:BIB_BCE4CC57F51F]
 
Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure.
Harari A., Enders F.B., Cellerai C., Bart P.A., Pantaleo G., 2009. Journal of Virology, 83 (7) pp. 2862-2871.
[DOI][WoS][Pmid][serval:BIB_26C61DC56F12]
 
Immunologic and virologic characterization of an ART-treated HIV-I patients cohort with long-term control of viremia
Kinloch S., Cellerai C., Yerly S., Byrne P., Carroll A., Stauss H., Johnson A., Harari A., Pantaleo G., 2009. p. 277 dans AIDS Vaccine 2009, Retrovirology. Peer-reviewed.
[DOI][WoS][serval:BIB_BE5742C21373]
2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
Harari A., Bart P. A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., Burnet S., Cellerai C., Erlwein O., Barber T. et al., 2008. Journal of Experimental Medicine, 205 (1) pp. 63-77. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3CD56A6881FB]
 
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.
Bart P.A., Goodall R., Barber T., Harari A., Guimaraes-Walker A., Khonkarly M., Sheppard N.C., Bangala Y., Frachette M.J., Wagner R. et al., 2008. Vaccine, 26 (25) pp. 3153-3161. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB078A5AF88C]
 
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.
McCormack S., Stöhr W., Barber T., Bart P.A., Harari A., Moog C., Ciuffreda D., Cellerai C., Cowen M., Gamboni R. et al., 2008. Vaccine, 26 (25) pp. 3162-3174. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6443A01EDC31]
 
HIV-1-specific immune response.
Harari A., Pantaleo G., 2008. Advances in Pharmacology, 56 pp. 75-92.
[DOI][WoS][Pmid][serval:BIB_FFF7D277FB61]
 
Insight in the factors associated with the presence of protective antiviral T-cell response.
Harari A., Bellutti Enders F., Garcia M., Pantaleo G., 2008. pp. 56-57 dans 2007 ESCCA Abstracts, Cytometry Part B: Clinical Cytometry. Peer-reviewed.
[DOI][serval:BIB_DA980B112D0D]
 
Phenotype and function of protective T cell immune responses in HIV.
Betts M.R., Harari A., 2008. Current Opinion in HIV and AIDS, 3 (3) pp. 349-355.
[DOI][WoS][Pmid][serval:BIB_7CD7000E72C4]
 
Relationship between degranulation activity and content of granules in virus-specific CD8 T-cells : P39
Bellutti-Enders F., Harari A., Cellerai C., Pantaleo G., 2008. pp. 8S dans Annual Joint Meeting of the Swiss Societies for Pneumology, Paediatric Pneumology, Allergology and Immunology, Thoracic Surgery, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_7DAE1AFF758E]
 
Relationship between HLA genotype and the functional profile of Ag-specific CD8 T-cells : 39
Harari A., Cellerai C., Bellutti-Enders F., Pantaleo G., 2008. pp. 47S dans Annual Joint Meeting of the Swiss Societies for Pneumology, Paediatric Pneumology, Allergology and Immunology, Thoracic Surgery, Swiss Medical Weekly. Peer-reviewed.
[WoS][serval:BIB_743DD45FA7E0]
2007
 
Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype
Harari A., Cellerai C., Enders F. B., Kostler J., Codarri L., Tapia G., Boyman O., Castro E., Gaudieri S., James I. et al., 2007/10. Proceedings of the National Academy of Sciences of the United States of America, 104 (41) pp. 16233-8.
[DOI][WoS][Pmid][serval:BIB_B0591BC8253E]
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses
Precopio M. L., Betts M. R., Parrino J., Price D. A., Gostick E., Ambrozak D. R., Asher T. E., Douek D. C., Harari A., Pantaleo G. et al., 2007/06. Journal of Experimental Medicine, 204 (6) pp. 1405-16.
[URN][DOI][WoS][Pmid][serval:BIB_D1AFA81DDA61]
 
Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization
Cellerai C., Harari A., Vallelian F., Boyman O., Pantaleo G., 2007/04. European Journal of Immunology, 37 (4) pp. 1129-38.
[DOI][WoS][Pmid][serval:BIB_5B3CE29EF5FA]
 
Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure
Correa R., Harari A., Vallelian F., Resino S., Munoz-Fernandez M. A., Pantaleo G., 2007/01. AIDS, 21 (1) pp. 23-30.
[DOI][WoS][Pmid][serval:BIB_C9782122B74A]
2006
 
Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases
Pantaleo G., Harari A., 2006/05. Nature Reviews. Immunology, 6 (5) pp. 417-23.
[DOI][WoS][Pmid][serval:BIB_E848347E6AAF]
Diagnostic moderne de l'infection tuberculeuse: mesure de l'interferon-gamma. [Specific interferon-gamma assays: a modern tool for tuberculosis diagnosis]
Lurati Ruiz F., Audran R., Harari A., Spertini F., 2006/04. Revue Médicale Suisse, 2 (62) pp. 1042, 1044-7. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_17CB1235A525]
 
Clinical studies of experimental vaccines.
Bart P.A., Harari A., Pantaleo G., 2006. Current Opinion in Hiv and Aids, 1 (4) pp. 286-293.
[DOI][WoS][Pmid][serval:BIB_E8922002E905]
 
Functional signatures of protective antiviral T-cell immunity in human virus infections.
Harari A., Dutoit V., Cellerai C., Bart P.A., Du Pasquier R.A., Pantaleo G., 2006. Immunological Reviews, 211 pp. 236-254. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE2B6D903135]
 
Role of HIV-1-specific CD4 T cells.
Harari A., Cellerai C., Pantaleo G., 2006. Current Opinion In Hiv and Aids, 1 (1) pp. 22-27.
[DOI][WoS][Pmid][serval:BIB_AF649A5F6C06]
2005
 
Understanding what makes a good versus a bad vaccine
Harari A., Pantaleo G., 2005/09. European Journal of Immunology, 35 (9) pp. 2528-31.
[DOI][WoS][Pmid][serval:BIB_FE51441F1B0A]
 
HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells
Zimmerli S. C., Harari A., Cellerai C., Vallelian F., Bart P. A., Pantaleo G., 2005/05. Proceedings of the National Academy of Sciences of the United States of America, 102 (20) pp. 7239-44.
[DOI][WoS][Pmid][serval:BIB_81FC323D58B8]
 
Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence.
Harari A., Vallelian F., Meylan P.R., Pantaleo G., 2005. Journal of Immunology, 174 (2) pp. 1037-1045.
[WoS][Pmid][serval:BIB_43264304AE44]
Standardization of cytokine flow cytometry assays.
Maecker H.T., Rinfret A., D'Souza P., Darden J., Roig E., Landry C., Hayes P., Birungi J., Anzala O., Garcia M. et al., 2005. BMC Immunology, 6 p. 13. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_65F6E764F0F0]
2004
 
Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy
Harari A., Petitpierre S., Vallelian F., Pantaleo G., 2004/02. Blood, 103 (3) pp. 966-72.
[DOI][WoS][Pmid][serval:BIB_E4FE4405165A]
 
Cytomegalovirus (CMV)-specific cellular immune responses.
Harari A., Zimmerli S.C., Pantaleo G., 2004. Human immunology, 65 (5) pp. 500-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9A6BACAECA40]
 
Functional characterization of HIV-1-specific CD4 T cells
Harari A., Pantaleo G., 2004., EPHIS book.
[serval:BIB_707312959F9D]
 
Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load.
Harari A., Vallelian F., Pantaleo G., 2004. European journal of immunology, 34 (12) pp. 3525-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_67A085F19BA1]
2002
 
Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections.
Ellefsen K., Harari A., Champagne P., Bart P.A., Sékaly R.P., Pantaleo G., 2002/12. European journal of immunology, 32 (12) pp. 3756-3764. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_23749]
 
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection
Harari A., Rizzardi G. P., Ellefsen K., Ciuffreda D., Champagne P., Bart P. A., Kaufmann D., Telenti A., Sahli R., Tambussi G. et al., 2002/08. Blood, 100 (4) pp. 1381-7.
[DOI][WoS][Pmid][serval:BIB_A47337CF723B]
 
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy
Rizzardi G. P., Harari A., Capiluppi B., Tambussi G., Ellefsen K., Ciuffreda D., Champagne P., Bart P. A., Chave J. P., Lazzarin A. et al., 2002/03. Journal of Clinical Investigation, 109 (5) pp. 681-8.
[DOI][WoS][Pmid][serval:BIB_8F0AB4D335C7]
 
Antiviral memory T cell responses: correlation with protective immunity and implication for vaccine development.
Harari A., Ellefsen K., Champagne P., Nobile M., Pantaleo G., 2002. Advances in Experimental Medicine and Biology, 512 pp. 155-64. Peer-reviewed.
[WoS][Pmid][serval:BIB_23755]
 
Transepithelial transport of HIV-1 by M cells is receptor-mediated.
Fotopoulos G., Harari A., Michetti P., Trono D., Pantaleo G., Kraehenbuhl J.P., 2002. Proceedings of the National Academy of Sciences of the United States of America, 99 (14) pp. 9410-4. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F4A301E9B37]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University